Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Antibody Structure and Classes01:25

Antibody Structure and Classes

Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuromagnetic treatment of pain in refractory carpal tunnel syndrome: An electrophysiological and placebo analysis.

Journal of back and musculoskeletal rehabilitation·2012
Same author

Physical fitness and self-reported physical exercise among college men and women in 1987 and 1997.

Perceptual and motor skills·2002
Same author

Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution.

Journal of human genetics·2001
Same author

Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters.

Toxicology·2001
Same author

Characterization of binding of leukotriene C4 by human multidrug resistance protein 1: evidence of differential interactions with NH2- and COOH-proximal halves of the protein.

The Journal of biological chemistry·2001
Same author

Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity.

The Journal of biological chemistry·2001
Same journal

Impact of virtual case conferences between primary care clinicians and an interdisciplinary chronic pain clinic.

Canadian family physician Medecin de famille canadien·2026
Same journal

Canadian family physician Medecin de famille canadien·2026
Same journal

Predictors of high-performing family medicine clinics: Prospective cohort study in Alberta.

Canadian family physician Medecin de famille canadien·2026
Same journal

Acetylsalicylic acid use for artial fibrillation and bleeding risk.

Canadian family physician Medecin de famille canadien·2026
Same journal

Clinical practice guidelines: Important tools to teach the art of medicine.

Canadian family physician Medecin de famille canadien·2026
Same journal

Paratonia in advanced dementia: Challenges and evidence-based interventions.

Canadian family physician Medecin de famille canadien·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Monoclonal antibodies.

S P Cole

    Canadian Family Physician Medecin De Famille Canadien
    |January 26, 2011
    PubMed
    Summary
    This summary is machine-generated.

    Hybridoma monoclonal antibody (MAb) technology revolutionized medicine, enabling large-scale antibody production. While murine MAbs are widely used, challenges with human MAbs and new genetic engineering methods promise future advancements.

    More Related Videos

    In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
    08:53

    In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

    Published on: September 16, 2019

    Generation of Murine Monoclonal Antibodies by Hybridoma Technology
    09:42

    Generation of Murine Monoclonal Antibodies by Hybridoma Technology

    Published on: January 2, 2017

    Related Experiment Videos

    Last Updated: Jun 5, 2026

    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
    07:36

    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

    Published on: May 16, 2020

    In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
    08:53

    In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

    Published on: September 16, 2019

    Generation of Murine Monoclonal Antibodies by Hybridoma Technology
    09:42

    Generation of Murine Monoclonal Antibodies by Hybridoma Technology

    Published on: January 2, 2017

    Area of Science:

    • Immunology
    • Biotechnology
    • Medical Diagnostics

    Background:

    • Hybridoma technology enables the production of large quantities of pure, homogeneous monoclonal antibodies (MAbs).
    • Murine MAbs are extensively utilized in clinical and research settings, especially in oncology.
    • Conventional antiserum remains a viable and cost-effective option for certain applications.

    Purpose of the Study:

    • To review the impact and applications of hybridoma monoclonal antibody technology.
    • To discuss the advantages and limitations of murine and human MAbs.
    • To explore emerging genetic engineering approaches for antibody development.

    Main Methods:

    • Review of hybridoma technology and its applications.
    • Comparison of murine and human monoclonal antibodies.
    • Discussion of novel genetic engineering techniques for antibody production.

    Main Results:

    • Monoclonal antibody technology has significantly advanced clinical and laboratory medicine.
    • Murine MAbs are widely adopted, particularly in oncology.
    • Technical hurdles impede the widespread clinical use of human MAbs, though they offer therapeutic advantages.
    • Genetic engineering presents promising future directions for antibody development.

    Conclusions:

    • Hybridoma technology has transformed antibody production for medical and research use.
    • Despite challenges with human MAbs, ongoing research and genetic engineering hold significant potential for future therapeutic and diagnostic applications.